Design a selective chemotherapeutic strategy for approximately 30% of non- small cell lung cancers that are MTAP-deficient using the antitumor L- alanosine as a potent inhibitor of DE NOVO AMP synthesis. Determine if tumors lacking the ability to salvage MTAP are more sensitive to inhibition of del novo adenine nucleotide synthesis than normal tissues and determine if unique antibiotic L-alanosine can cause selective depletion of adenine nucleotides in MTAP-deficient tumors.
Showing the most recent 10 out of 1825 publications